Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma

van der Watt,Pauline  J.; Zemanay,Widaad; Govender,Dhirendra; Hendricks,Denver  T.; Parker,M. I.; Leaner,Virna  D.

doi:10.3892/or.2014.3231

Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma

Authors:
- Pauline J. van der Watt
- Widaad Zemanay
- Dhirendra Govender
- Denver T. Hendricks
- M. I. Parker
- Virna D. Leaner
View Affiliations

Affiliations: Division of Medical Biochemistry, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, Division of Anatomical Pathology, Faculty of Health Sciences, University of Cape Town, NHLS-Groote Schuur Hospital, Cape Town, South Africa
Published online on: June 4, 2014 https://doi.org/10.3892/or.2014.3231
Pages: 730-738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The nuclear export receptor, Crm1 (exportin 1), is involved in the nuclear translocation of proteins and certain RNAs from the nucleus to the cytoplasm and is thus crucial for the correct localisation of cellular components. Crm1 has recently been reported to be highly expressed in certain types of cancers, yet its expression in oesophageal cancer has not been investigated to date. We investigated the expression of Crm1 in normal and tumour tissues derived from 56 patients with human oesophageal squamous cell carcinoma and its functional significance in oesophageal cancer cell line models. Immunohistochemistry revealed that Crm1 expression was significantly elevated in oesophageal tumour tissues compared to normal tissues and its localisation shifted from predominantly nuclear to nuclear and cytoplasmic. Real‑time RT‑PCR revealed that Crm1 expression was elevated at the mRNA level. To determine the functional significance of elevated Crm1 expression in oesophageal cancer, its expression was inhibited using siRNA, and a significant decrease in cell proliferation was observed associated with G1 cell cycle arrest and the induction of apoptosis. Similarly, leptomycin B (LMB) treatment resulted in the effective killing of oesophageal cancer cells at nanomolar concentrations. Normal oesophageal epithelial cells, however, were much less sensitive to Crm1 inhibition with siRNA and LMB. Together, this study reveals that Crm1 expression is increased in oesophageal cancer and is required for the proliferation and survival of oesophageal cancer cells.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Ossareh-Nazari B, Bachelerie F and Dargemont C: Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 278:141–144. 1997. View Article : Google Scholar : PubMed/NCBI
4	Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M and Nishida E: CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:308–311. 1997. View Article : Google Scholar : PubMed/NCBI
5	Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ and Wahl GM: A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–1672. 1999. View Article : Google Scholar : PubMed/NCBI
6	Saji M, Vasko V, Kada F, Allbritton EH, Burman KD and Ringel MD: Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun. 332:167–173. 2005. View Article : Google Scholar : PubMed/NCBI
7	van der Watt PJ, Maske CP, Hendricks DT, et al: The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 124:1829–1840. 2009.
8	Noske A, Weichert W, Niesporek S, et al: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yao Y, Dong Y, Lin F, et al: The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 21:229–235. 2009.PubMed/NCBI
10	Shen A, Wang Y, Zhao Y, Zou L, Sun L and Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 65:153–159. 2009. View Article : Google Scholar : PubMed/NCBI
11	Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH and Sun YJ: Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 32:E3152009.PubMed/NCBI
12	Zhou F, Qiu W, Yao R, et al: CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol. 30:7262013. View Article : Google Scholar : PubMed/NCBI
13	Tai YT, Landesman Y, Acharya C, et al: CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 28:155–165. 2014. View Article : Google Scholar : PubMed/NCBI
14	Roberts BJ, Hamelehle KL, Sebolt JS and Leopold WR: In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 16:95–101. 1986. View Article : Google Scholar : PubMed/NCBI
15	Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB and Murli S: Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69:510–517. 2009. View Article : Google Scholar : PubMed/NCBI
16	Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W and Daelemans D: Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem. 16:9487–9497. 2008.PubMed/NCBI
17	Allred DC, Brown P and Medina D: The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res. 6:240–245. 2004.
18	Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A and Sorensen FB: Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochem Cytochem. 59:750–760. 2011. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C^_T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Jones GJ, Heiss NS, Veale RB and Thornley AL: Amplification and expression of the TGF-α, EGF receptor and c-myc genes in four human oesophageal squamous cell carcinoma lines. Biosci Rep. 13:303–312. 1993.
21	Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
22	Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida M and Horinouchi S: Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem. 272:29742–29751. 1997. View Article : Google Scholar : PubMed/NCBI
23	van der Watt PJ and Leaner VD: The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta. 1809:316–326. 2011.PubMed/NCBI
24	Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J and Ozcelik H: p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 51:71–79. 1998. View Article : Google Scholar : PubMed/NCBI
25	Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K and Kobayashi M: Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol. 26:287–292. 1996. View Article : Google Scholar : PubMed/NCBI
26	Lecane PS, Kiviharju TM, Sellers RG and Peehl DM: Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate. 54:258–267. 2003. View Article : Google Scholar : PubMed/NCBI
27	Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B and Lain S: Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene. 18:7378–7386. 1999. View Article : Google Scholar : PubMed/NCBI
28	Kuusisto HV, Wagstaff KM, Alvisi G, Roth DM and Jans DA: Global enhancement of nuclear localization-dependent nuclear transport in transformed cells. FASEB J. 26:1181–1193. 2011. View Article : Google Scholar : PubMed/NCBI